Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilazodone Switch Study in MDD
NCT01742832Phase 2Completed
- Sponsor
- University of Chicago
- Start
- May 2013
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilazodone in major depressive disorder (MDD) (2 arms), sponsored by University of Chicago. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started May 2013; status: completed.
02
Drugs
vilazodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01742832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01742832.